Skip to main content

Table 3 Comparison of HPV prevalence in ICC specimens among studies conducted in Italy

From: Human Papilloma Virus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy

Author

Year

Tecnique used

Samples analized

HPV + cases (%)

HPV16

HPV18

HPV31

HPV33

HPV45

HPV58

HPVx

Other

M.I.

Gioele G. Garzetti et al.[13]

1998

PCR primers for HPV6, 11, 16, 18, 31, 33, 34, 35, 42, 51, 56 & 58

32

22

(68.8%)

16

(50.0%)

4

(12.5%)

2

(6.3%)

0

(0.0%)

-

0

(0.0%)

1

(3.1%)

0

(0.0%)

1

(3.1%)

Ciotti et al.[14]

2005

MY09/11, GP5+/6+

102

92

(90.2%)

59

(57.8%)

8

(7.8%)

6

(5.9%)

10

(9.8%)

3

(2.9%)

4

(3.9%)

0

(0.0%)

14

(13.7%)

12

(11.8%)

Del mistro et al.[15]

2006

GP5+/6+

48

44

(91.7%)

32

(66.7%)

4

(8.3%)

1

(2.1%)

4

(8.3%)

2

(4.2%)

2

(4.2%)

0

(0.0%)

4

(8.3%)

5

(10.4%)

Tornesello et al.[16]

2006

MY09/11 & GP5+/6+

65

53

(81.5%)

39

(60.0%)

4

(6.2%)

3

(4.6%)

4

(6.2%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

4

(6.2%)

1

(1.5%)

Gargiulo et al.[17]

2007

Linear array

31

29

(93.5%)

19

(61.3%)

4

(12.9%)

3

(9.7%)

4

(12.9%)

4

(12.9%)

1

(3.2%)

0

(0.0%)

28

(90.3%)

14

(45.2%)

Present study

2008

SPF10/DEIA/LIPA25

134

121

(90.3%)

72

(53.7%)

13

(9.7%)

7

(5.2%)

4

(3.0%)

6

(4.5%)

6

(4.5%)

4

(3.0%)

17

(12.7%)

6

(4.5%)

AVERAGE

412

361

(87.6%)

237

(57.5%)

37

(9.0%)

22

(5.3%)

26

(6.3%)

15

(3.6%)

13

(3.2%)

5

(1.2%)

67

(16.3%)

39

(9.5%)

  1. M.I.: Multiple infections. A multiple infection is counted once on every type involved. In example: HPV16&74 is counted as n = 1 in HPV16 and n = 1 in HPV74. The sum of the total % may exceed 100%.
  2. Gioele G. Garzetti et al.: Histology: 32 patients with FIGO Stage I and IIA SCC who had undergone primary radical hysterectomy and bilateral oophorectomy. Patients with no SCC histotype were excluded. M.I.: HPV16&31.
  3. Ciotti et al.: Histology: 102 SCC. M.I.: n = 4 HPV31&54; n = 3 HPV16&33; n = 3 HPV16&18; n = 1 HPV33&54; n = 1 HPV16&53. Other: n = 8 single infections (n = 3 HPV56; n = 2 HPV52, n = 1 HPV51, n = 1 HPV35, n = 1 HPV73) and n = 6 in M.I. (n = 4 HPV31&54, n = 1 HPV33&54, n = 1 HPV16&53).
  4. Del Mistro et al.: Histology: 48 SCC (43 SCC and 5 Adenocarcinomas). M.I.: n = 5 (n = 3 HPV16&18; n = 1 HPV16&31; n = 1 HPV56&70).Other: n = 2 in single infections (n = 1 HPV35; n = 1 HPV52) and n = 2 in M.I: (n = 1 HPV56; n = 1 HPV70).
  5. Tornesello et al.: 65 SCC. M.I.: n = 1 HPV16&73. Other: n = 3 single infections (n = 1 HPV35, n = 1 HPV62, n = 1 HPV82) and n = 1 M.I (HPV16&73).
  6. Gargiulo et al.: Histology: 31 cervical cancer samples analyzed with non histological sub classification specified. M.I.: n = 14, already counted in Table 2 of the article. They do not specify all the M.I as some were up to more the 5 HPV types. Only the most prevalent ones are described. Other: n = 5 HPV52; n = 4 HPV61; n = 3 HPV70; n = 3 HPV84; n = 2 HPV51; n = 2 HPV62; n = 1 HPV35; n = 1 HPV39; n = 1 HPV56; n = 1 HPV53; n = 1 HPV55; n = 1 HPV66; n = 1 HPV67; n = 1 HPV81; n = 1 HPV89.
  7. Present study: Histology: 134 samples (122 SCC, 17 Adenocarcinomas, 1 adenosquamous and 4 other histological types). M.I.: n = 6 (n = 1 HPV16&18; n = 1 HPV45&51; n = 1 HPV31&42; n = 1 HPV31&52; n = 1 HPV6&53&66; n = 1 HPV53&56&58). Other: n = 9 in single infections (n = 2 HPV35; n = 2 HPV51; n = 2 HPV52; n = 1 HPV42; n = 1 HPV56; n = 1 HPV70) and n = 8 in M.I (n = 2 HPV53; n = 1 HPV51; n = 1 HPV52; n = 1 HPV42; n = 1 HPV6; n = 1 HPV66; n = 1 HPV56).
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us